These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15552525)

  • 1. Benefits and risks of biological agents: lymphomas.
    van Vollenhoven RF
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S122-5. PubMed ID: 15552525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
    Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
    Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety issues related to emerging therapies for rheumatoid arthritis.
    Keystone EC
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S148-50. PubMed ID: 15552529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate.
    Nakashima C; Tanioka M; Takahashi K; Miyachi Y
    Clin Exp Dermatol; 2008 Jul; 33(4):437-9. PubMed ID: 18485021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.
    Symmons DP; Silman AJ
    Arthritis Rheum; 2004 Jun; 50(6):1703-6. PubMed ID: 15188344
    [No Abstract]   [Full Text] [Related]  

  • 9. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study.
    Hellgren K; Iliadou A; Rosenquist R; Feltelius N; Backlin C; Enblad G; Askling J; Baecklund E
    Ann Rheum Dis; 2010 Apr; 69(4):654-9. PubMed ID: 19439429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment.
    Bassetti S; Wasmer S; Hasler P; Vogt T; Nogarth D; Frei R; Widmer AF
    J Rheumatol; 2005 Nov; 32(11):2125-9. PubMed ID: 16265689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.
    Brown SL; Greene MH; Gershon SK; Edwards ET; Braun MM
    Arthritis Rheum; 2002 Dec; 46(12):3151-8. PubMed ID: 12483718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].
    D'Alessandro G; Bianco MR; Politis S; Ferrandina C; Rossi G; Altomare E
    Reumatismo; 2006; 58(1):59-61. PubMed ID: 16639489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab: new indication. In rheumatoid arthritis: for a few patients, with close monitoring.
    Prescrire Int; 2007 Oct; 16(91):186-8. PubMed ID: 17926823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
    Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
    Dermatology; 2008; 217(4):380. PubMed ID: 18849606
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.
    Ljung L; Simard JF; Jacobsson L; Rantapää-Dahlqvist S; Askling J;
    Arthritis Rheum; 2012 Jan; 64(1):42-52. PubMed ID: 21898355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Guidelines for usage of biological agents for treatment of rheumatoid arthritis].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():444-7. PubMed ID: 15799396
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.